Published 1 year ago

Alzheimer's drug trial shown to slow cognitive decline in long fight against dementia

Summary by The Daily Star

An experimental Alzheimer's disease drug from Eisai (4523.T) and Biogen (BIIB.O) slowed cognitive decline in a closely-watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday.

0 Articles

All

Left

Center

Right

BBC News

Alzheimer's drug hailed as momentous breakthrough

Lecanemab is the first drug to remove damage, but there are questions around its impact, side effects and use.

1 year ago·United Kingdom

Read Full Article

News18 India

Lecanemab: Drug Developed to Treat Alzheimer’s Slows Progression of Disease

Researchers have heralded Lecanemab, a drug that slows the destruction of the human brain due to Alzheimer's disease. Alzheimer's disease is the most common form of dementia and the Lecanemab has ushered in a new era of drugs that could treat the disease

1 year ago·India

Read Full Article

The Guardian

Drug slows cognitive decline in Alzheimer’s patients, study reveals

Antibody therapy lecanemab removes clumps of protein called beta amyloid that builds up in brain

1 year ago·London, United Kingdom

Read Full Article

CTV News

Drug slows Alzheimer's but can it make a real difference?

An experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening, researchers reported Tuesday – but it remains unclear how much difference that might make in people's lives.

1 year ago·Canada

Read Full Article

The Independent

Scientists hail breakthrough as drug proven to slow Alzheimer’s disease

‘This is the first drug that provides a real treatment option,’ says leading researcher

1 year ago·London, United Kingdom

Read Full Article

Reuters

Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focus

An experimental Alzheimer's drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of serious side effects for certain patients, according to detailed data presented on Tuesday.

1 year ago·United Kingdom

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.